REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
06/16/2025
Back to search
Official data from USPTO
QUELL
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
QUELL
ST13
US500000088372290Class
5, 40, 42, 44
Filing
88372290
Registration
6077717
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
32
Latest update
06/17/2025
Trademark type
Word
Nice classes
5, 40, 42, 44
Filing date
04/04/2019
Registration date
06/16/2020
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/16/2020
Last transaction
06/17/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
Drawing code
4
Owner type
99
Owner location
London, GB
Examiner
BAYLISS,HUNTER A
Law office
M40
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Quell Therapeutics Limited
Representatives
Steven T. Shelton SHELTON IP
Technical classification
Nice Classes
Class 5Class 40Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical and biological preparations for diagnosticmedicaltherapeuticprophylactic use for inducing tolerance to a transplant and for treatingpreventing or ameliorating transplant rejectionGraft-versus-Host Disease (GvHD)autoimmune and allergic diseaseundesired inflammation and inflammatory diseasefor promoting tissue repair and regeneration; veterinary preparations for diagnosticmedicaltherapeuticprophylactic use for inducing tolerance to a transplant and for treatingpreventing or ameliorating transplant rejectionGraft-versus-Host Disease (GvHD)autoimmune and allergic diseaseundesired inflammation and inflammatory diseasefor promoting tissue repair and regeneration; preparations for cell therapypreparations comprising T cells having an immunosuppressive phenotype; preparations for gene therapy; pharmaceuticalmedicalclinical preparations for use in treatmentamelioration and prophylaxis of immune system related diseases and disorders; preparations for therapies to modulate the immune system for inducing tolerance to a transplant and for treatingpreventing or ameliorating transplant rejectionGraft-versus-Host Disease (GvHD)autoimmune and allergic diseaseundesired inflammation and inflammatory diseasefor promoting tissue repair and regeneration; preparations for therapies for autoimmune conditions and immunological disorders; cancer preparationschimeric antigen receptors and therapeutic preparations thereof for inducing tolerance to a transplant and for treatingpreventing or ameliorating transplant rejectionGraft-versus-Host Disease (GvHD)autoimmune and allergic diseaseundesired inflammation and inflammatory diseasefor promoting tissue repair and regeneration; diagnostic kits consisting of monoclonal antibodies for use in disease testing and for inducing tolerance to a transplant and for treatingpreventing or ameliorating transplant rejectionGraft-versus-Host Disease (GvHD)autoimmune and allergic diseaseundesired inflammation and inflammatory diseasefor promoting tissue repair and regeneration; preparations for therapeutic delivery of nucleic acids for inducing tolerance to a transplant and for treatingpreventing or ameliorating transplant rejectionGraft-versus-Host Disease (GvHD)autoimmune and allergic diseaseundesired inflammation and inflammatory diseasefor promoting tissue repair and regeneration; viral or nucleic acid vectors for therapeutic or prophylactic purposes and preparations containing such vectors for inducing tolerance to a transplant and for treatingpreventing or ameliorating transplant rejectionGraft-versus-Host Disease (GvHD)autoimmune and allergic diseaseundesired inflammation and inflammatory diseasefor promoting tissue repair and regeneration; preparations for genetically modifying human and animal cells for diagnostic and medical purposes; preparations of blood or cells extracted from humans or animals which have been adapted for therapeutic purposes; none of the foregoing having any relation to pain treatment or management
Class 40
Manufacturing and processing pharmaceuticals for others; manufacturing and processing biologicalbiotechnological and biopharmaceutical preparations for others; processing of biological tissuebloodcellgenetic material for others; production and manufacture of viral vectors for others; production and manufacture of gene therapy products for others; custom manufacture of pharmaceutical and biological preparations for others; none of the foregoing having any relation to pain treatment or management
Class 42
advisory services relating to gene therapy and design; Scientific and technological servicesresearch and design in the field of T cells with an immunosuppressive phenotype and transplant rejectionGraft-versus-Host Disease (GvHD)autoimmune and allergic diseaseundesired inflammation and inflammatory diseasefor promoting tissue repair and regeneration; industrial analysis and research in the field of cell therapy; medical and veterinary research services in the field of the manipulation of cells within a laboratory or research facility to enable the cells to be used for therapeutic purposes; scientific research in the development of new therapies in the field of autoimmuneimmunological disorders and to modulate the immune system; scientific research in human and animal cell therapy; scientific research in human and animal gene therapy; scientific research into vectors and preparations for manipulating and adapting human and animal cells; scientific and technological servicesdesign in the field of cell therapy; none of the foregoing having any relation to pain treatment or management
Class 44
Medical services; medical services in the field of immunology; medical services in the field of surgery; medical services in the field of autoimmune diseases and conditions; medical servicesin the field oftissue transplant surgery; collection and preservation of biological tissuebloodcells and genetic materials; medical diagnosis of transplant rejectionGraft-versus-Host Disease (GvHD)autoimmune and allergic diseaseundesired inflammation and inflammatory diseasefor promoting tissue repair and regeneration; Medical treatment of transplant rejectionGraft-versus-Host Disease (GvHD)autoimmune and allergic diseaseundesired inflammation and inflammatory diseasefor promoting tissue repair and regeneration; providing information and data for diagnosis and medical treatment of transplant rejectionGraft-versus-Host Disease (GvHD)autoimmune and allergic diseaseundesired inflammation and inflammatory diseasefor promoting tissue repair and regeneration; gene and nucleic acid delivery or modification for therapeutic purposes; medical treatmentadministering cell or gene therapies; advisory services in the field of health as it relates to cell or gene therapy; medical advisory services relating to cell or gene therapy; none of the foregoing having any relation to pain treatment or management
Publications
History of USPTO decisions and trademark events.
32 publications found
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
01/25/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
01/25/2023
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
01/25/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
01/25/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
01/25/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
01/25/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
06/16/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/31/2020
PUBO
PUBLISHED FOR OPPOSITION
03/31/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/11/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/25/2020
XAEC
EXAMINER'S AMENDMENT ENTERED
02/25/2020
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
02/25/2020
GNEA
EXAMINERS AMENDMENT E-MAILED
02/25/2020
CNEA
EXAMINERS AMENDMENT -WRITTEN
02/25/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/13/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/13/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/13/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
01/23/2020
GNRT
NON-FINAL ACTION E-MAILED
01/23/2020
CNRT
NON-FINAL ACTION WRITTEN
01/23/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/30/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/30/2019
ALIE
ASSIGNED TO LIE
12/30/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/09/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
06/24/2019
GNRT
NON-FINAL ACTION E-MAILED
06/24/2019
CNRT
NON-FINAL ACTION WRITTEN
06/24/2019
DOCK
ASSIGNED TO EXAMINER
06/14/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/22/2019
NWAP
NEW APPLICATION ENTERED
04/08/2019
Continuous trademark protection
Get notified about every new filing that threatens QUELL or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.